Y Intercept Hong Kong Ltd Invests $682,000 in Ascendis Pharma A/S $ASND

Y Intercept Hong Kong Ltd acquired a new position in Ascendis Pharma A/S (NASDAQ:ASND) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 3,951 shares of the biotechnology company’s stock, valued at approximately $682,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. RA Capital Management L.P. raised its stake in shares of Ascendis Pharma A/S by 1.7% in the first quarter. RA Capital Management L.P. now owns 10,281,496 shares of the biotechnology company’s stock worth $1,602,474,000 after purchasing an additional 168,752 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its stake in shares of Ascendis Pharma A/S by 12.0% in the first quarter. T. Rowe Price Investment Management Inc. now owns 3,053,824 shares of the biotechnology company’s stock worth $475,970,000 after purchasing an additional 328,278 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Ascendis Pharma A/S by 0.6% in the first quarter. Massachusetts Financial Services Co. MA now owns 1,877,917 shares of the biotechnology company’s stock worth $292,692,000 after purchasing an additional 10,366 shares during the last quarter. Invesco Ltd. raised its stake in shares of Ascendis Pharma A/S by 3.7% in the first quarter. Invesco Ltd. now owns 1,198,478 shares of the biotechnology company’s stock worth $186,795,000 after purchasing an additional 42,465 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of Ascendis Pharma A/S by 10.4% in the first quarter. Goldman Sachs Group Inc. now owns 585,581 shares of the biotechnology company’s stock worth $91,269,000 after purchasing an additional 55,164 shares during the last quarter.

Ascendis Pharma A/S Price Performance

NASDAQ:ASND opened at $197.75 on Thursday. The business has a fifty day simple moving average of $201.49 and a two-hundred day simple moving average of $182.82. Ascendis Pharma A/S has a 1 year low of $118.03 and a 1 year high of $216.45. The company has a market capitalization of $12.20 billion, a P/E ratio of -38.32 and a beta of 0.44.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.49. The firm had revenue of $216.28 million during the quarter, compared to analysts’ expectations of $163.17 million. As a group, analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ASND shares. Bank of America increased their price objective on Ascendis Pharma A/S from $227.00 to $230.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. JPMorgan Chase & Co. increased their price target on Ascendis Pharma A/S from $260.00 to $264.00 and gave the company an “overweight” rating in a research report on Thursday, October 9th. Wall Street Zen raised Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $295.00 price target (up from $289.00) on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Finally, Wedbush increased their price target on Ascendis Pharma A/S from $212.00 to $220.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $249.80.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.